BIOSECURE Act - The potential $3.6bn+ gap, Impact on Jobs and Skills shifts with Amber Tong, Senior Editor at EndPoint News

BIOSECURE Act - The potential $3.6bn+ gap, Impact on Jobs and Skills shifts with Amber Tong, Senior Editor at EndPoint News

In this episode,Charles talks with Amber Tong, a senior editor at Endpoints News, about how the Biosecure Act could impact the biotech and pharma sectors.

Amber shares thoughts on how this law could change U.S.-China biopharma ties, jobs, and making medicines. We also look into how things are changing in this area, who might benefit or not, and the big global tensions that affect these shifts.

Here's what you are in for:

00:00 Introduction

00:33 Welcoming the Guest

02:36 Discussing the Biosecure Act

04:34 Impact on the Biotech Industry

07:17 Geopolitical Tensions and Historical Context

16:09 Potential Winners and Losers

35:16 Future Predictions and Conclusion

About Amber Tong

Amber Tong is a senior editor at Endpoints News, which is a global specialty publication covering the biotech and pharmaceutical industries. She's a reporter/editor with more than six years of experience covering the biopharma industry, with a particular focus on the growing role China plays on the global stage.


Amber is also at BIO San Diego 2024, go say hi.


Useful Information on BIOSECURE

Endpoints' latest articles:


BIO: China tensions, fixing gene therapy’s business model, and the stop-start market recovery

https://endpts.com/see-you-at-bio-china-tensions-fixing-gene-therapys-business-model-and-the-stop-start-market-recovery/

WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down

https://endpts.com/wuxi-became-a-critical-partner-to-biopharma-companies-theyre-not-ready-if-the-us-cracks-down/

The US could upend biopharma manufacturing. WuXi rivals have an opening

https://endpts.com/the-us-could-upend-biopharma-manufacturing-wuxi-rivals-have-an-opening/

US-China tensions threaten to ensnare additional Chinese biopharma contractors

https://endpts.com/us-china-tensions-threaten-to-ensnare-additional-chinese-biopharma-contractors/

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

https://endpts.com/new-biosecure-draft-features-2032-grandfather-clause-five-year-grace-period-for-added-companies/

BIO CEO defends the organization's about-face on the Biosecure Act

https://endpts.com/bio-ceo-defends-the-organizations-about-face-on-the-biosecure-act/

Medicxi backs Chinese biotech's next-gen KRAS G12C drug with $40M injection

https://endpts.com/medicxi-backs-d3-bios-next-gen-kras-g12c-drug-with-40m-injection/


About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.

He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-borsens-finest
24fragor
svd-tech-brief
avanzapodden
badfluence
uppgang-och-fall
lastbilspodden
fill-or-kill
rss-inga-dumma-fragor-om-pengar
rss-kort-lang-analyspodden-fran-di
tabberaset
rss-dagen-med-di
bathina-en-podcast
rikatillsammans-om-privatekonomi-rikedom-i-livet
kapitalet-en-podd-om-ekonomi
affarsvarlden
borsmorgon